treatment strategy Included: hydroxychloroquine, naproxen, and oseltamivir for outpatient patients with Covid 19
Not Applicable
Completed
- Conditions
- COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20201202049566N1
- Lead Sponsor
- Ghoum University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Patients with Covid 19 with concurrent disease confirmation
Positive PCR test
Bilateral lung involvement
Having symptoms of the disease
Oxygen saturation level: below 90
does not participate in another trial
least basic literacy
Exclusion Criteria
Lack of cooperation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Having symptoms indicative of cough, shortness of breath, fever. Timepoint: Daily - 14 days after treatment. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie hydroxychloroquine's antiviral effects in SARS-CoV-2 infection?
How does the combination of hydroxychloroquine, naproxen, and oseltamivir compare to standard outpatient therapies for mild-to-moderate COVID-19?
Which biomarkers could predict response to hydroxychloroquine-based treatment regimens in SARS-CoV-2 positive patients?
What are the potential drug-drug interactions and adverse event profiles of hydroxychloroquine, naproxen, and oseltamivir in outpatient COVID-19 management?
How do the therapeutic effects of oseltamivir compare to other neuraminidase inhibitors in SARS-CoV-2 viral clearance strategies?